Keros Therapeutics Financials - Benzinga

Keros Therapeutics Inc

KROSNASDAQ

Trade with Public

Trade with Public

$11.03

-0.20-1.78%

At close: Aug 28, 5:00 PM EST

$11.03

N/A

After Hours: Aug 28, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Keros Therapeutics Financials

Keros Therapeutics (KROS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of $(0.76) per share

Benzinga Newsdesk

PRO
Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(1.02) by 18.63 percent. This is a 133.43 percent decrease over earnings of $3.62 per share

Benzinga Newsdesk

PRO
CORRECTION: Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $385.000K Miss $2.757M Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.60) by 42.62 percent. This is a 24.56 percent increase over losses of $(1.14) per share

Benzinga Newsdesk

Keros Therapeutics: Q4 Earnings Insights

Benzinga Insights

PRO
Keros Therapeutics Q3 EPS $(0.18) Beats $(1.05) Estimate, Sales $14.262M Beat $3.800M Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(1.05) by 82.81 percent. This is a 87.23 percent increase over losses of $(1.41) per share

Benzinga Newsdesk

PRO
Keros Therapeutics Q2 EPS $(0.76) Beats $(1.11) Estimate, Sales $18.168M Beat $2.767M Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.11) by 31.78 percent. This is a 39.2 percent increase over losses of $(1.25) per share from

Benzinga Newsdesk